Eagle Pharmaceuticals, Inc. (EGRX): Price and Financial Metrics

Eagle Pharmaceuticals, Inc. (EGRX)

Today's Latest Price: $47.31 USD

0.81 (1.74%)

Updated Nov 27 1:00pm

Add EGRX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

EGRX Stock Summary

  • EGRX's current price/earnings ratio is 124.86, which is higher than 93.51% of US stocks with positive earnings.
  • Price to trailing twelve month operating cash flow for EGRX is currently 23.23, higher than 80.23% of US stocks with positive operating cash flow.
  • In terms of volatility of its share price, EGRX is more volatile than merely 17.38% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Eagle Pharmaceuticals Inc, a group of peers worth examining would be SMTC, SSTI, TTGT, MITK, and MANH.
  • Visit EGRX's SEC page to see the company's official filings. To visit the company's web site, go to www.eagleus.com.

EGRX Stock Price Chart Interactive Chart >

Price chart for EGRX

EGRX Price/Volume Stats

Current price $47.31 52-week high $62.41
Prev. close $46.50 52-week low $33.80
Day low $46.26 Volume 65,200
Day high $47.48 Avg. volume 167,772
50-day MA $45.72 Dividend yield N/A
200-day MA $46.26 Market Cap 616.45M

Eagle Pharmaceuticals, Inc. (EGRX) Company Bio

Eagle Pharmaceuticals focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company was founded in 2007 and is based in Woodcliff Lake, New Jersey.

EGRX Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$47.31$55.38 19%

Below please find a table outlining a discounted cash flow forecast for EGRX, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Eagle Pharmaceuticals Inc ranked in the 50th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 19.17%. The most interesting components of our discounted cash flow analysis for Eagle Pharmaceuticals Inc ended up being:

  • The business' balance sheet suggests that 5% of the company's capital is sourced from debt; this is greater than merely 15.76% of the free cash flow producing stocks we're observing.
  • As a business, Eagle Pharmaceuticals Inc experienced a tax rate of about 36% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than 92.45% of stocks generating free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of Eagle Pharmaceuticals Inc? See AMED, SNY, INBP, QDEL, and LCI.

EGRX Latest News Stream

Event/Time News Detail
Loading, please wait...

EGRX Latest Social Stream

Loading social stream, please wait...

View Full EGRX Social Stream

Latest EGRX News From Around the Web

Below are the latest news stories about Eagle Pharmaceuticals Inc that investors may wish to consider to help them evaluate EGRX as an investment opportunity.

Eagle Pharmaceuticals commences $25M accelerated share repurchase

Eagle Pharmaceuticals (EGRX) approved a $25M accelerated share repurchase transaction with JPMorgan as part of the existing $160M share repurchase program. $25M share repurchase would represent ~5% of the basic outstanding shares.Upon completion of the ASR, Eagle will have bought back a total of approximately $205 million of its stock...

Seeking Alpha | September 24, 2020

Eagle Pharma's TREAKISYM RTD formulation OK'd in Japan; launch expected in January 2021

Eagle Pharmaceuticals' (EGRX) marketing partner, SymBio Pharmaceuticals has received regulatory approval for TREAKISYM ready-to-dilute ((RTD)) (250 ml) liquid formulation from the Pharmaceuticals and Medical Devices Agency ((PMDA)) in Japan.As a result, the company will receive a $5M milestone payment. Product launch is expected in January 2021.The approval covers all indications for...

Seeking Alpha | September 23, 2020

Eagle Pharmaceuticals’ Japanese Licensing Partner, SymBio, Receives Approval of TREAKISYM Ready-To-Dilute (“RTD”) Formulation, with Launch Expected in January 2021

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX) today announced that its marketing partner, SymBio Pharmaceuticals Limited (“SymBio”), has received regulatory approval for TREAKISYM ready-to-dilute (“RTD”) (250 ml) liquid formulation from the Pharmaceuticals and Medical Devices Agency (“PMDA”) in Japan. The approval covers all indications for which TREAKISYM is currently approved (low-grade non-Hodgkin’s lymphoma, mantle cell lymphoma

Business Wire | September 23, 2020

Eagle Pharmaceuticals to Present at Upcoming September 2020 Healthcare Conferences

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX) today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at two upcoming conferences in September. At the Morgan Stanley 18th Annual Virtual Global Healthcare Conference: Date: Monday, September 14, 2020 Time: 3:00 p.m. Eastern Time Webcast: https://morganstanley.webcasts.com/starthere.jsp?ei=1362588&tp_key=91c8ad632b At the

Business Wire | September 8, 2020

Eagle Pharmaceuticals Announces Publication of Preclinical Study of Intranasal Dantrolene in Journal of Alzheimer’s Disease

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that preclinical research on dantrolene sodium was published today in the peer-reviewed Journal of Alzheimer’s Disease.1 The article reported results from an academic-based study that demonstrated dantrolene sodium administered intranasally improved both memory and cognition in a mouse model of Alzheimer’s disease. Eagle markets a formulation of dantrolene sodium but did

Business Wire | August 19, 2020

Read More 'EGRX' Stories Here

EGRX Price Returns

1-mo 2.45%
3-mo 19.53%
6-mo -8.97%
1-year -19.10%
3-year -18.67%
5-year -48.37%
YTD -21.25%
2019 49.12%
2018 -24.58%
2017 -32.67%
2016 -10.52%
2015 472.06%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8733 seconds.